IQISH technology, based on Dako’s fast IQISH hybridization buffer chemistry, reduces the evaluation time from two days to three and a half hours, facilitating quick initiation of the
The study observed a statistically significant relationship between injected dose and antitumor activity of the investigational agent. ATLAB medical affairs head Pr. Jean-François Chatal said, "ATL101 shows a
Tresiba is the new once-daily basal insulin with an ultra-long duration of action for the treatment of type 1 and type 2 diabetes. Tresiba successfully achieved equivalent reductions
Coyote is expected to file IND application for CNS-102 for amyotrophic lateral sclerosis (ALS) therapy in the fourth quarter of 2013 and commence a Phase 1 study in
Production of MU1140 using fermentation has also lead to the discovery of a new purification process for the product, according to Oragenics. Lantibiotic MU1140 is intended to be
The supplement that is expected to last for 24 to 48 hours is developed to improve endurance, strength, and energy in males. Hokutou CEO Eugene Collings said the
The final step in the solubilization partnership between the companies is expected to aid Dow to commercially supply solubility enabling excipients. Dow senior R&D director Bob Maughon said,
According to the deal, Bristol-Myers will earn $438m upfront payment from Reckitt Benckiser for the exclusive rights to sell, distribute and market the products for a period of
Pioglitazone Tablets USP 15mg, 30mg & 45mg and Pioglitazone Hydrochloride + Metformin Hydrochloride Tablets, 15mg (base)/500mg & 15mg(base)/850mg are ready for launch. Both the products are indicated for
Uceris that contains a locally acting glucocorticosteroid, budesonide, in a novel oral tablet formulation has obtained FDA approval. Santarus research and development executive vice president Wendell Wierenga said,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.